Compare Abbott Laboratories (ABT) vs Ralph Lauren Corp (RL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Ralph Lauren Corp — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while Ralph Lauren Corp trades at $385.59 (market cap $23.53B). The key difference: Abbott Laboratories is far larger — about 7.1× Ralph Lauren Corp's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | RL | |
|---|---|---|
Market Cap | $166.94B | $23.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $414.25 |
52-Week Low | $82.57 | $283.34 |
Enterprise Value | $193.69B | $24.47B |
Dividend Yield | 2.63% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Ralph Lauren (RL) trades at $395.31, down 0.73% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.80 surpassing expectations. Revenue growth accelerated to $7.08 billion in 2025, while net income margin improved to 10.49%. Analyst consensus remains strongly bullish with a $446.25 price target, representing 13% upside potential from current levels.
RL presents a compelling growth story with expanding margins and strategic initiatives driving performance. Key risks include consumer discretionary spending sensitivity and competitive pressures in the apparel sector. The company's digital expansion and Next Great Chapter strategy provide catalysts for continued outperformance, though macroeconomic headwinds could impact near-term results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
